Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026PR Newswire•04/09/2026•12:000 ShareWhiz InsightsGenerateNo content available.
